Cointime

PDS Biotechnology Corporation

company

About

PDS Biotechnology Announces Treatment of First Patient with PDS0101.

  • 11 - 50

Highlights

Total Funding Amount
$25M
Funding Rounds
1
Investors
1

Details

Last Funding Type
Post-IPO Debt
Last Funding Money Raised
$25M
Industries
Biotechnology,Health Care,Pharmaceutical
Founded date
Jan 1, 2005
Number Of Employee
11 - 50
Operating Status
Active

PDS Biotechnology Corporation is a biopharmaceutical company. It develops immunotherapies for cancer and other infectious diseases. It develops products to prevent and treat cervical, ovarian, melanoma, leukemia, pancreatic, oral, multiple myeloma, anal, vulvar, and penile cancers. The company offers PDS0101, a treatment for HPV-related cancers; PDS0102, a pandemic influenza vaccine; and PDS0103, a line of immunotherapy products for non-viral cancers.

PDS Biotechnology Corporation was founded in 2005 and is headquartered in North Brunswick, New Jersey.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$25M
PDS Biotechnology Corporation has raised a total of $25M in funding over 2 rounds. Their latest funding was raised on Aug 24, 2022 from a Post-IPO Debt round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Aug 24, 2022 Post-IPO Debt $25M 1 Horizon Technology Finance — Detail

Investors

Number of Lead Investors
Number of Investors
1
1
PDS Biotechnology Corporation is funded by 1 investors. Horizon Technology Finance are the most recent investors.
Investor Name Lead Investor Funding Round
Horizon Technology Finance Yes Post-IPO Debt
Cointime
Chủ Đề
Công Ty